MEK抑制剂-话题@MedSci

#MEK抑制剂#

22篇内容 | 973人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2204677, encodeId=803c22046e70f, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a> <a href='/topic/show?id=7bab1144686a' target=_blank style='color:#2F92EE;'>#妥拉美替尼#</a>, objectTitle=大咖谈 | MEK抑制剂妥拉美替尼研发历程简介, objectType=article, longId=825524, objectId=a1228255241b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240514/1715677048620_5579292.png, objectUrl=/article/show_article.do?id=a1228255241b, replyNumber=0, likeNumber=3, createdTime=17小时前, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a1228255241b, moduleTitle=大咖谈 | MEK抑制剂妥拉美替尼研发历程简介, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1228255241b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2201612, encodeId=8ff822016128a, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a> <a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=MEK抑制剂单药治疗为BRAF V600E突变甲状腺乳头状癌伴肺转移患者带来长期缓解, objectType=article, longId=824293, objectId=467b82429371, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-filling-form-U2MAYRK.jpg, objectUrl=/article/show_article.do?id=467b82429371, replyNumber=0, likeNumber=9, createdTime=2024-05-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=467b82429371, moduleTitle=MEK抑制剂单药治疗为BRAF V600E突变甲状腺乳头状癌伴肺转移患者带来长期缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=467b82429371)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1512744, encodeId=fd0c1512e4457, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识, objectType=article, longId=732817, objectId=fd3ce32817fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd3ce32817fa, replyNumber=0, likeNumber=43, createdTime=2022-07-21, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd3ce32817fa, moduleTitle=Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd3ce32817fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512743, encodeId=6d431512e438a, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, objectType=article, longId=731840, objectId=fa30e31840a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa30e31840a0, replyNumber=0, likeNumber=30, createdTime=2022-07-10, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa30e31840a0, moduleTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa30e31840a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512742, encodeId=1a0f1512e4299, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤, objectType=article, longId=724283, objectId=8cc1e24283bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cc1e24283bf, replyNumber=0, likeNumber=31, createdTime=2022-04-16, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cc1e24283bf, moduleTitle=J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cc1e24283bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512741, encodeId=f0a11512e4106, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, objectType=article, longId=300803, objectId=cb143008036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb143008036b, replyNumber=0, likeNumber=37, createdTime=2022-03-16, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb143008036b, moduleTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb143008036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512740, encodeId=c0661512e40e2, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, objectType=article, longId=293561, objectId=cf2c293561b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf2c293561b4, replyNumber=0, likeNumber=37, createdTime=2022-01-09, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf2c293561b4, moduleTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf2c293561b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512739, encodeId=33a21512e39b0, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, objectType=article, longId=206683, objectId=000c20668335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=000c20668335, replyNumber=0, likeNumber=53, createdTime=2021-02-04, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=000c20668335, moduleTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=000c20668335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512738, encodeId=91a21512e385b, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, objectType=article, longId=206376, objectId=d9952063e6c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9952063e6c2, replyNumber=0, likeNumber=31, createdTime=2021-01-30, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9952063e6c2, moduleTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9952063e6c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512737, encodeId=73851512e37dd, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, objectType=article, longId=206081, objectId=4595206081b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4595206081b2, replyNumber=0, likeNumber=31, createdTime=2021-01-24, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4595206081b2, moduleTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4595206081b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512736, encodeId=31421512e36a0, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=Lancet oncol：RAF-MEK抑制剂在携带RAS/RAF突变的多种肿瘤中的抗肿瘤活性, objectType=article, longId=202766, objectId=2fe5202e6622, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fe5202e6622, replyNumber=0, likeNumber=32, createdTime=2020-11-03, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fe5202e6622, moduleTitle=Lancet oncol：RAF-MEK抑制剂在携带RAS/RAF突变的多种肿瘤中的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fe5202e6622)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512735, encodeId=b9401512e3586, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, objectType=article, longId=201779, objectId=f6f5201e7983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6f5201e7983, replyNumber=0, likeNumber=24, createdTime=2020-10-08, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6f5201e7983, moduleTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6f5201e7983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512734, encodeId=d8c31512e343d, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=MEK抑制剂Selumetinib获得FDA突破疗法指定治疗丛状神经纤维瘤, objectType=article, longId=163506, objectId=9a621635067e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a621635067e, replyNumber=0, likeNumber=47, createdTime=2019-04-04, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a621635067e, moduleTitle=MEK抑制剂Selumetinib获得FDA突破疗法指定治疗丛状神经纤维瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a621635067e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512733, encodeId=d0a51512e33b4, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药, objectType=article, longId=162939, objectId=156a1629396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=156a1629396a, replyNumber=0, likeNumber=36, createdTime=2019-03-26, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=156a1629396a, moduleTitle=Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=156a1629396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512732, encodeId=fb371512e324b, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, objectType=article, longId=158891, objectId=8a5b15889101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a5b15889101, replyNumber=0, likeNumber=38, createdTime=2019-01-27, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a5b15889101, moduleTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a5b15889101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512731, encodeId=80a51512e3167, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤, objectType=article, longId=145835, objectId=24c4145835bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24c4145835bc, replyNumber=0, likeNumber=34, createdTime=2018-08-05, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24c4145835bc, moduleTitle=EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24c4145835bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512730, encodeId=d2ae1512e3041, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, objectType=article, longId=137007, objectId=d64a13e007c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64a13e007c3, replyNumber=0, likeNumber=41, createdTime=2018-05-04, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64a13e007c3, moduleTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d64a13e007c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512729, encodeId=2c541512e2929, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变, objectType=article, longId=125006, objectId=5ee4125006c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ee4125006c9, replyNumber=0, likeNumber=31, createdTime=2017-12-30, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ee4125006c9, moduleTitle=EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ee4125006c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512728, encodeId=07971512e28e8, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=EUR J Cancer：657例黑色素瘤患者NRAS的增益分析并评估其对MEK抑制剂的敏感性, objectType=article, longId=124480, objectId=bca6124480a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bca6124480a4, replyNumber=0, likeNumber=27, createdTime=2017-12-26, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bca6124480a4, moduleTitle=EUR J Cancer：657例黑色素瘤患者NRAS的增益分析并评估其对MEK抑制剂的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bca6124480a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1512727, encodeId=85641512e2762, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制剂#</a>, objectTitle=Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药, objectType=article, longId=115437, objectId=65d511543e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65d511543e88, replyNumber=0, likeNumber=33, createdTime=2017-10-10, rootId=0, userName=ms2186806800017884, userId=318b10497059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65d511543e88, moduleTitle=Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65d511543e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MEK抑制剂

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#MEK抑制剂# #妥拉美替尼#

大咖谈 | MEK抑制剂妥拉美替尼研发历程简介

17小时前发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#甲状腺乳头状癌# #MEK抑制剂#

MEK抑制剂单药治疗为BRAF V600E突变甲状腺乳头状癌伴肺转移患者带来长期缓解

2024-05-03发表于上海

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识

2022-07-21

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤

2022-07-10

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤

2022-04-16

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效

2022-03-16

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS

2022-01-09

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗

2021-02-04

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效

2021-01-30

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益

2021-01-24

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

Lancet oncol：RAF-MEK抑制剂在携带RAS/RAF突变的多种肿瘤中的抗肿瘤活性

2020-11-03

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤

2020-10-08

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

MEK抑制剂Selumetinib获得FDA突破疗法指定治疗丛状神经纤维瘤

2019-04-04

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药

2019-03-26

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者

2019-01-27

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤

2018-08-05

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤

2018-05-04

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变

2017-12-30

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

EUR J Cancer：657例黑色素瘤患者NRAS的增益分析并评估其对MEK抑制剂的敏感性

2017-12-26

ms2186806800017884 (审核中...)

前往app查看评论内容

#MEK抑制剂#

Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药

2017-10-10

科室
- - 订阅+
  - 更多科室
工具
服务